Redeye interviewed Neola Medical’s CEO, Hanna Sjöström, following the company’s Q3 2026 report. We discussed the report, the Breakthrough Device Designation and upcoming studies for the Neola device.
$NEOLA
redeye.se/research/1193796/n…
287
Lytix raised NOK80m at NOK8.00 (~12% dilution), ~80% from top holders, removing the financing overhang before full NeoLIPA data at ESMO IO (15 Dec). Runway into Q4 2027; phase III still needs a partner.
Fair value in the report. $LYTIX
redeye.se/research/1193777/l…
359
Smart Eye Q3: sales in line (+33% organic), all profit measures beat; first positive EBIT since 2015. Auto license revenue +150% y/y; royalties down q/q (seasonal). SEK40m savings programme from 2027.
Fair value in the report. $SEYE
redeye.se/research/1193654/s…
2
375
A cancer vaccine (SELLAS' GPS) showed a survival benefit as AML maintenance in a randomised phase III: median OS 24.0 vs 14.7 months. Supports Mendus' vididencel and its funding/partnering backdrop; not a near-term rival.
Fair value in the report. $IMMU
redeye.se/research/1193708/m…
374
IRLAB Q3: costs below estimate, cash SEK90.6m. A 2026 deal is now less likely; ~30% staff cut, more BD focus. Mesdopetam deal moved to 2027, more dilution. Otsuka-funded LIFT-PD readout mid-2027; cash lasts beyond it.
Fair value in the report. $IRLAB
redeye.se/research/1193605/i…
371
Redeye has interviewed Fable Media Group’s CEO, Carl Magnusson, about the Q3 report highlights, the suspension of operations in Brazil following the provisional ban on online betting and casino, the adjusted guidance and the outlook for new markets and the dividend.
$FABLE
redeye.se/research/1193539/f…
522
ExpreS2ion Q3: revenue/EBIT miss on lower grants; burn in line. Phase I fully enrolled, clean safety, responses in 12 of 13, though strength varies more; readout now Q1 2027. Phase II needs a partner or new equity.
Fair value in the report. $EXPRS2
redeye.se/research/1192942/e…
1
568
GiG Software trades below Redeye's Fair Value estimate of SEK 4.7 per share and has Market Edge scores of 4 for Value (Attractively Priced) and 4 for Momentum (Strong). We spoke with our analyst about what he sees as the main challenges with the 888Africa acquisition, what stood out in the Q3 results, and other key topics.
This is a premium article, included in our paid plans from SEK 99/month
$GIG
redeye.se/research/1193612/g…
503
Redeye intervjuade Corline Biomedicals VD, Henrik Nittmar, där vi diskuterade bolagets Q3-rapport, den finansiella guidningen för 2026 och 2027 samt growth initiative.
$CLBIO
redeye.se/research/1193598/c…
503
Lytix Q3: NeoLIPA met its primary endpoint (interim pCR 44% vs ~20% historically); full data at ESMO IO on 15 Dec. Stronger hand in phase III partnering. Cash into Q2 2027; we assume an equity raise.
Base case NOK16 (15), fair value NOK15 (14). $LYTIX
redeye.se/research/1193535/l…
513
Corline Q3: sales SEK2.4m (+81% y/y), below our estimate but as the soft H2 guidance signalled. Binding rolling Kardium orders improve visibility; we expect a Q4 rebound. Globe ramp slower than we expected.
Base case SEK24 (25), fair value SEK19. $CLBIO
redeye.se/research/1193418/c…
534
Dynavox restated organic growth after inconsistent FX use. IFRS figures, margins and targets unchanged, but Q3 organic growth is now 9% (13%) and N. America 11% (16%): no 2026 acceleration. EBIT margin 17.4% still above target.
No estimate changes. $DYVOX
redeye.se/research/1193456/d…
633
Saniona has FDA clearance to start Phase I of SAN2465, its GABA-A α5 NAM for major depression; first participant before year-end. A positive step that keeps Saniona on track, with both priority programmes soon in the clinic.
Q3 report next week. $SANION
redeye.se/research/1193444/s…
642
Redeye intervjuar Medivirs vd Jens Lindberg om Q3-rapporten, vad BeOnes data för BGB-B2033 innebär för fostrox, status för FLEX-HCC samt den kommande MIV-701-datan.
$MVIR
redeye.se/research/1193309/m…
614
Redeye intervjuar Intervaccs VD gällande bolagets Q3-rapport.
$IVACC
redeye.se/research/1193538/i…
680
Intervacc launched a UK strangles alert scheme with Cambridge University and JData: weekly regional outbreak alerts for vets. Should help vaccination awareness; no noticeable near-term sales impact expected.
Base case SEK1.6. $IVACC
redeye.se/research/1193400/i…
592
Sprint Bioscience Q3: no surprises; EBIT SEK-14.7m with no revenue in the quarter, cash SEK77.5m. Busy partnering autumn and new VRK1 data at ENA this week. We move the assumed VPS34 deal into 2027.
Base case SEK5.2, fair value SEK5.0 (5.1). $SPRINT
redeye.se/research/1192338/s…
545
Freemelt Q3: in line with preliminary figures. Backlog now >SEK100m, mostly Manufacturing, largely for 2027 delivery. A fully guaranteed SEK152m rights issue funds the scale-up; positive cash flow targeted 2029.
Forecasts and valuation unchanged. $FREEM
redeye.se/research/1193374/f…
1
649
Redeye pratar med Eolus vd Per Witalisson om bolagets Q3-rapport, där de sista betalningarna från Centennial Flats gav ett starkt kvartal och en nettokassa på SEK530m. Vi går igenom försäljningen och nedskrivningarna i USA och vägen fram till transaktioner för Ölme och Valpene. Vi pratar också om varför Eolus har lagt till 592 MW energilager och om erfarenheten ger en fördel mot nya aktörer på BESS-marknaden. Per kommenterar även stigande elprisprognoser, efterfrågan från datacenter, nya turbinplattformar och vad investerare kan förvänta sig av 2027.
$EOLU
redeye.se/research/1193306/e…
518
Eolus Q3: all Centennial Flats payments received, lifting net cash to SEK530m. EBIT SEK112m, below our estimate on Ölme timing and ~SEK40m US write-downs. More upbeat CEO, several 2027 deals lined up.
$EOLU
redeye.se/research/1193339/e…
581




















